Laurus Labs reported strong financial results for fiscal 2026, driving a 30 percent gain in its share price. Growth in contract manufacturing and a better product mix supported the performance.
The Indian pharmaceutical company is directing ₹3,000 crore toward capacity expansion. Focus areas include high-value contract development and manufacturing services.
These services are expected to double their share of total revenue by 2030. Analysts have raised earnings estimates while keeping a buy recommendation on the stock.
The results reflect continued expansion across multiple business segments. Brokerage firms remain positive on the outlook for the company.